Skip to Content
Merck
CN
  • Studying KCNQ1 Mutation and Drug Response in Type 1 Long QT Syndrome Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Studying KCNQ1 Mutation and Drug Response in Type 1 Long QT Syndrome Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Methods in molecular biology (Clifton, N.J.) (2017-10-24)
Heming Wei, Jianjun Wu, Zhenfeng Liu
ABSTRACT

Patient-specific human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs) are becoming a valuable model for studying inherited cardiac arrhythmias. Type 1 long-QT syndrome is associated with the genetic variants of KCNQ1 gene that encodes Kv7.1, the α-subunit of the voltage-gated potassium channel QKT subfamily member 1 that channels the slow component of the outwardly rectifying K+ channel current in cardiac myocytes. Patient- or disease-specific hiPSC-CM model could facilitate the characterization of the genotype-phenotype relationships and testing of individualized drug responses.Here, we describe the methods in the generation of hiPSC-CMs, molecular and electrophysiological characterizations of their cellular phenotypes associated with KCNQ1/Kv7.1 defects, and evaluation of the effects of K+ channel-specific drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Albumin human, Cellastim S, recombinant, expressed in rice, lyophilized powder, suitable for cell culture, low endotoxin, ≥96% (SDS-PAGE)